Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)

Inclusion Criteria: * Adults aged 18 years and older with chronic (\> 3months, \< 18 months) macular edema secondary to branch retinal vein occlusion * Patients who at baseline have a BSCVA in the study eye between 20/320 and equivalent to 20/40, using an ETDRS chart measured at 4 meters * Patients who at baseline have a chronic macular edema (\> 3 months) in the study eye with the following characteristics as determined by fluorescein angiography: * Evidence that the macular edema extends under the geometric center of the foveal avascular zone. * Evidence that the edema is only secondary to BRVO (no other relevant ocular diseases, e.g. uveitis). * Patients who at baseline have a chronic macular edema (\> 3 months) in the study eye with the following characteristics as determined by optical coherence tomography (OCT 3): * Evidence that central macular thickness is \> 225 μm. * Ability of subject to understand character and individual consequences of clinical trial. * Signed and dated informed consent of the subject must be available before start of any specific trial procedures. * For women with childbearing potential, adequate contraception (negative pregnancy test result, serum or urine at trial entry, after treatment and at end of study). * Only one eye of a patient may be included to this trial. Exclusion Criteria: * Patients who at baseline * Have a relevant ocular disease which may be associated with increased intraocular VEGF levels (namely uveitis, neovascular glaucoma, neovascular age-related macular degeneration, diabetic retinopathy, diabetic maculopathy, ocular ischemic syndrome, and others) * Have a relevant systemic disease which may be associated with increased systemic VEGF levels (namely all malignancies) * Had previous treatment for macular edema (laser, triamcinolone, vitrectomy) * Pregnancy and lactation. * History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product. * Participation in other clinical trials within the last 3 months. * Medical or psychological condition that would not permit completion of the trial or signing of informed consent. * Arterial hypertension refractory to medical treatment